An observational study in Sacroiliitis and Sacroiliac Joint Dysfunction, sponsored by CornerLoc. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by CornerLoc · Observational
A prospective study on the use of the TransLoc 3D SI Joint Fusion System for patients with sacroiliac joint disruptions or degenerative sacroiliitis.
Multicenter, prospective, post-market surveillance study on the TransLoc 3D Sacroiliac Joint Fusion System including two treatment arms: 1) Lateral-Oblique TransLoc 3D Screw(s), 2) Lateral Oblique TransLoc 3D Screw with Posterior Device (Hybrid). Data from this post-market study will be used to support knowledge of clinical efficacy and improvement with the use of TransLoc 3D Sacroiliac Joint Fusion System.
42 studies on the registry are indexed under Sacroiliitis; 11 are open to participants now.
This study's planned enrollment of 240 is above the median of 120 across 13 observational studies indexed under Sacroiliitis.
Browse Sacroiliitis studies →CornerLoc is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Consecutive enrollment of all patients within inclusion criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects meeting all of the following inclusion criteria by the end of the screening phase should be considered for admission to the study:
Exclusion Criteria:
Patient will not be entered into the study if they meet one of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receiving the TransLoc 3D Screw(s) version will receive screw(s) placed lateral-obliquely into the intended SI joint.
Device: TransLoc 3D
Patients receiving the TransLoc 3D Hybrid construct will receive one 3D-printed titanium screw placed lateral-obliquely and one 3D-printed titanium posterior device across the same sacroiliac joint.
Device: TransLoc 3D
TransLoc 3D SI Joint Fusion System
Clinical improvement at 12 months defined by a composite score of functional status, pain, and safety events.
Functional improvement and pain score have long been the standard for SI joint improvement measures. Multiple functional improvement scales will be assessed throughout the study.
Time frame: 12 months
Absence of Serious Adverse Events (SAEs)
Demonstrate safety as defined by Serious Adverse Events (SAEs).
Time frame: From the time informed consent is signed through 12 months.
Absence of study-related adverse events
Evaluate any study-related adverse events for the duration of the study.
Time frame: 6 months, 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2023 (actual). Primary completion is estimated for Aug 2027, 46 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Dec 2025 → Aug 2027 and completion Jul 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.